Metipranolol

Metipranolol is a nonselective and orally active β-adrenergic receptor antagonist. Metipranolol can be used for hypertension and glaucoma research^[1][2]. In Vitro: In vitro β1- and β2-adrenoceptor antagonism is evaluated using the guinea pig atrium and the rat uterus, respectively. The respective pA₂ values are 8.3 and 8.4^[2].
Metipranolol significantly reduces iron/ascorbate-induced lipid peroxidation in rat brain homogenates with an IC₅₀ value of 6.9 μM . Metipranolol also concentration-dependently inhibits sodium nitroprusside-stimulated lipid peroxidation in rat brain homogenates, displaying an IC₅₀ value of 25.1 μM^[3]. In Vivo: At postnatal day 35 (P35), rd10 mice given daily subcutaneous injections of 40 mg/kg of Metipranolol has reduction in markers of nitrosative stress, fewer TUNEL-positive cells, increased outer nuclear layer thickness, and substantially more staining for rhodopsin. At P50, Metipranolol-treated rd10 mice has decreased 3-nitrotyrosine staining in the retina, increased immunostaining for cone arrestin, a marker for cone photoreceptors, and significantly higher scotopic and photopic b-wave amplitudes at the highest stimulus intensity. At P65, cone density is significantly higher in Metipranolol-treated versus vehicle-injected rd10 mice^[1].